Evolved resistance to colistin and its loss due to genetic reversion in Pseudomonas aeruginosa

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Lee, Ji Young ^a   Park, Young Kyoung ^a   Chung, Eun Seon ^a   Na, In Young ^a   Ko, Kwan Soo ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; COLISTIN;

ANTIBIOTIC RESISTANCE; BACTERIAL GENOME; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; GENETIC SELECTION; GENETICS; MUTATION; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; COLISTIN; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, BACTERIAL; GENOME, BACTERIAL; MUTATION; PSEUDOMONAS AERUGINOSA; SELECTION, GENETIC;

EID: 84967113379     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep25543     Document Type: Article

References (58)

1. Center for Disease Dynamics, Economics and Policy. State of the world's antibiotics. 2015. CDDEP: Washington DC (2015). Available at: http://cddep.org/publications/state-worlds-antibiotics-2015#sthash.8vhKO3xz.dpbs. Date of access: 06/04/2016.
2. Alekshun, M. N., Levy, S. B. Molecular mechanisms of antibacterial multidrug resistance. Cell 128, 1037-1050 (2007).
3. Davies, J. E. Origins, acquisition and dissemination of antibiotic resistance determinants. Ciba. Found. Symp. 207, 15-27 (1999).
4. Anderson, D. Persistence of antibiotic resistant bacteria. Curr. Opin. Microbiol. 6, 452-456 (2003).
5. Fernández, L., Breidenstein, E. B., Hancock, R. E. Creeping baselines and adaptive resistance to antibiotics. Drug Resist. Updat. 14, 1-21 (2001).
6. Wong, A., Rodrigue, N., Kassen, R. Genomics of adaptation during experimental evolution of the opportunistic pathogen Pseudomonas aeruginosa. PLos Genet. 8, e1002928 (2012).
7. Poole, K. Pseudomonas aeruginosa: resistance to the max. Front. Microbiol. 2, 65 (2012).
8. Skida, A., Markogiannakis, A., Plachouras, D., Daikos, G. L. Adaptive resistance to cationic compounds in Pseudomonas aeruginosa. Int. J. Antimicrob. Agents. 37, 187-193 (2011).
9. Bernal, P., Molina-Santiago, C., Daddaoua, A., Llamas, M. A. Antibiotic adjuvants: identification and clinical use. Microb. Biotechnol. 6, 445-449 (2013).
10. Hocquet, D. et al. MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob. Agents Chemother. 47, 1371-1375 (2003).
11. Yuan, W. et al. Cell wall thickening is associated with adaptive resistance to amikacin in methicillin-resistant Staphylococcus aureus clinical isolates. J. Antimicrob. Chemother. 68, 1089-1096 (2013).
12. Fernández, L. et al. Adaptive resistance to the "last hope" antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParS. Antimicrob. Agents Chemother. 54, 3372-3382 (2010).
13. Moore, R. A., Chan, L., Hancock, R. E. Evidence for two distinct mechanisms of resistance to polymyxin B in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 26, 539-945 (1984).
14. Muhle, S. A., Tam, J. P. Design of Gram-negative selective antimicrobial peptides. Biochemistry 40, 5777-5785 (2001).
15. Storm, D. R., Rosentha, K. S., Swanson, P. E. Polymyxin and related peptide antibiotics. Annu. Rev. Biochem. 46, 723-763 (1977).
16. Stein, A., Raoult, D. Colistin: an antimicrobial for the 21st century? Clin. Infect. Dis. 35, 901-902 (2006).
17. Falagas, M. E., Michalopoulos, A. Polymyxins: old antibiotics are back. Lancet 367, 633-634 (2006).
18. Alina, P., Yeshayahu, N., Tsilia, L. Identification of pathogenic bacteria in blood culture; comparison between conventional and PCR methods. J. Microbiol. Methods 78, 325-30 (2009).
19. Biswas, S., Brunel, J. M., Dubus, J. C., Reynaud-Gaubert, M., Rolain, J. M. Colistin: an update on the antibiotic of the 21st century. Expert. Rev. Anti. Infect. Ther. 10, 917-934 (2012).
20. Lee, J. Y., Lim, M. H., Heo, S. T., Ko, K. S. Repeated isolation of Pseudomonas aeruginosa isolates resistant to both polymyxins and carbapenems from 1 patient. Diagn. Microbiol. Infect. Dis. 72, 267-271 (2012).
21. Snitkin, E. S. et al. Genomic insights into the fate of colistin resistance and Acinetobacter baumannii during patient treatment. Genome Res. 23, 1155-1162 (2013).
22. Kim, Y. et al. In vivo emergence of colistin resistance in Acinetobacter baumannii clinical isolates of sequence type 357 during colistin treatment. Diagn. Microbiol. Infect. Dis. 79, 362-366 (1994).
23. Boll, M., Radziejewska-Lebrecht, J., Warth, C., Krajewska-Pietrasik, D., Mayer, H. 4-Amino-4-deoxy-L-arabinose in LPS of enterobacterial R-mutants and its possible role for their polymyxin reactivity. FEMS Immunol. Med. Microbiol. 8, 329-341 (1994).
24. Nummila, K., Kilpelaïnen, I., Zähringer, U., Vaara, M., Helander, I. M. Lipopolysaccharides of polymyxin B-resistant mutants of Escherichia coli are extensively substituted by 2-aminoethyl pyrophosphate and contain aminoarabinose in lipid A. Mol. Microbiol. 16, 271-278 (1995).
25. Moskowitz, S. M., Ernst, R. K., Miller, S. I. PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J. Bacteriol. 186, 575-579 (2004).
26. McPhee, J. B. et al. Contribution of the PhoP-PhoQ and PmrA-PmrB two-component regulatory systems to Mg2+induced gene regulation in Pseudomonas aeruginosa. J. Bacteriol. 188, 3995-4006 (2006).
27. Abraham, N., Kwon, D. H. A single amino acid substitution in PmrB is associated with polymyxin B resistance in clinical isolate of Pseudomonas aeruginosa. FEMS Microbiol. Lett. 298, 249-254 (2009).
28. Barrow, K., Kwon, D. H. Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53, 5150-5154 (2009).
29. Schurek, K. N. et al. Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53, 4345-4351 (2009).
30. Lee, J. Y., Ko, K. S. Mutations and expression of PmrAB and PhoPQ related with colistin resistance in Pseudomonas aeruginosa clinical isolates. Dign. Microbiol. Infect. Dis. 78, 271-276 (2014).
31. Fernández, L. et al. The two-component system CprRS senses cationic peptides and triggers adaptive resistance in Pseudomonas aeruginosa independently of ParRS. Antimicrob. Agents Chemother. 56, 6212-6222 (2012).
32. Lee, J. Y. et al. Development of colistin resistance in pmrA-, phoP-, parR-and cprR-inactivated mutants of Pseudomonas aeruginosa. J. Antimicrob. Chemother. 69, 2966-2971 (2014).
33. Lee, J. Y., Na, I. Y., Park, Y. K., Ko, K. S. Genomic variations between colistin-susceptible and-resistant Pseudomonas aeruginosa clinical isolates and their effects on colistin resistance. J. Antimicrob. Chemother. 69, 1248-1256 (2014).
34. Liu, Y. Y. et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect. Dis. 16, 161-168 (2016).
35. Moffatt, J. H. et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob. Agents. Chemother. 54, 4971-4977 (2010).
36. Moffatt, J. H. et al. Insertion sequence ISAba1 is involved in colistin resistance and loss of lipolysaccharide in Acinetobacter baumannii. Antimicrob. Agents. Chemother. 55, 3022-3024 (2011).
37. Moffatt, J. H. et al. Lipopolysaccharide-deficient Acinetobacter baumannii shows altered signaling through host Toll-like receptors and increased susceptibility to the host antimicrobial peptide LL-37. Infect. Immun. 81, 684-689 (2013).
38. Olaitan, A. O. et al. Worldwide emergence of colistin resistance in Klebsiella pneumoniae from healthy humans and patients in Lao PDR, Thailand, Israel, Nigeria and France owing to inactivation of the PhoP/PhoQ regulator mgrB: an epidemiological and molecular study. Int. J. Antimicrob. Agents 44, 500-507 (2014).
39. Mathee, K. et al. Dynamics of Pseudomonas aeruginosa genome evolution. Proc. Natl. Acad. Sci. USA 105, 3100-3105 (2008).
40. Gutu, A. D. et al. Polymyxin resistance of Pseudomonas aeruginosa phoQ mutants is dependent on additional two-component regulatory systems. Antimicrob. Agents Chemother. 57, 2204-2215 (2013).
41. Choi, M. J., Ko, K. S. Mutant prevention concentrations of colistin for Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumopniae clinical isolates. J. Antimicrob. Chemother. 69, 275-277 (2014).
42. Gales, A. C., Jones, R. N., Sader, H. S. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gramnegative pathogens: results from the SENTRY antimicrobial surveillance program (2006-09). J. Antimicrob. Chemother. 6, 2070-2074 (2011).
43. Cai, Y., Chai, D., Wang, R., Liang, B., Bai, N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J. Antimicrob. Chemother. 67, 1607-1615 (2012).
44. Lee, J. Y., Song, J. H., Ko, K. S. Identification of nonclonal Pseudomonas aeruginosa isolates with reduced colistin susceptibility in Korea. Microb. Drug. Resist. 17, 299-304 (2011).
45. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: Twenty-fourth Information Supplement M100-S24. CLSI, Wayne, PA, USA (2014).
46. Humphrey, E. et al. Fitness of Escherichia coli strains carrying expressed and partially silent IncN and IncP1 plasmids. BMC Microbiol. 12, 53 (2012).
47. Beceiro, A. et al. Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii. Antimicrob. Agents chemother. 58, 518-526 (2014).
48. El Hamidi, A., Tirsoaga, A., Novikov, A., Hussein, A., Caroff, M. Microextraction of bacterial lipid A: easy and rapid method for mass spectrometric characterization. J. Lipid Res. 46, 1773-1778 (2005).
49. Ernst, R. K. et al. Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science 286, 1561-1565 (1999).
50. Beceiro, A. et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob. Agents Chemother. 55, 3370-3379 (2011).
51. Ng, P. C., Henikoff, S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 31, 3812-3814 (2003).
52. Sim, N. L. et al. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res. 40, W452-W457 (2012).
53. Song, J. H. et al. Identification of essential genes in Streptococcus pneumoniae by allelic replacement mutagenesis. Mol. Cells 19, 365-374 (2005).
54. Datsenko, K. A., Wanner, B. L. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. USA 97, 6640-6645 (2000).
55. Schweizer, H. P. Escherichia-Pseudomonas shuttle vectors derived from pUC18/19. Gene 97, 109-121 (1991).
56. Chung, C. T., Niemela, S. L., Miller, R. H. One-step preparation of competent Escherichia coli: transformation and storage of bacterial cells in the same solution. Proc. Natl. Acad. Sci. USA 86, 2172-2175 (1989).
57. Muller, C., Plésiat, P., Jeannot, K. A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and ?-lactams in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 55, 1211-1221 (2011).
58. Steinberg, D. A. et al. Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activity. Antimicrob. Agents Chemother. 41, 1738-1742 (1997).